EUVIMEDEUVIMED entdecken
Crossref

Type-I interferon–activated NK cells control polycythemia vera in vivo

Johanna Lossa, Tina M Schnöder iD, Zora Ronge, Nelly Haasch, Katrin Hodapp, Federico Marini iD, Najla Abassi iD, Matthias M Gaida iD, Shin-Jye Lee, Alina Henrich iD, Michaela N Höhne-Wiechmann iD, Carlos Thull Mogollón und 11 weitere

Blood · 10.09.2026 · 148 (11) · 1454-1465

DOI: 10.1182/blood.2026033951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 10.09.2026. Verfasst von Johanna Lossa und 22 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Hauptthemen laut MEDLINE: Polycythemia Vera, Killer Cells, Natural, Interferon-alpha, Lymphocyte Activation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycythemia vera (PV) is a clonal hematopoietic stem cell disorder resulting in overproduction of erythrocytes. Although interferon alfa (IFN-α) has shown therapeutic efficacy in PV and other myeloproliferative neoplasms (MPN), its precise mechanism of action remains poorly understood. In this study, we identify natural killer (NK) cells as primary immune effectors responsive to IFN-α treatment in PV essential for disease control in vivo. Using a transgenic mouse model of PV, we demonstrate that IFN-α induces the expansion of CD27+ NK cells in the bone marrow. In patients with PV or essential thrombocythemia undergoing IFN-α therapy, the frequency of CD56bright NK cells is increased and correlates with the molecular response. Depletion of NK cells abrogated the therapeutic effects of IFN-α. In vitro experiments demonstrate that NK cells preferentially killed Jak2VF mutant hematopoietic stem and progenitor cells in a tumor necrosis factor-α–dependent manner and independent of IFN-γ or NKG2D. Notably, PV mice depleted of NK cells or lacking type-I interferon receptor on NK cells showed accelerated disease progression in the absence of exogenous IFN-α. This suggests that direct sensing of basal levels of type-I interferons by NK cells is essential for attenuating disease progression, emphasizing a critical role for NK cells in immune surveillance of MPN. These findings offer new insights into type-I interferon-mediated immune modulation in MPN and highlight the potential of NK cell activation to improve therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraKiller Cells, NaturalInterferon-alphaLymphocyte ActivationAnimalsHumansMiceJanus Kinase 2Mice, TransgenicHematopoietic Stem CellsTumor Necrosis Factor-alphaMice, Inbred C57BLThrombocythemia, Essential

Substanzen

Janus Kinase 2Interferon-alphaTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Institute of Immunology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  • Research Center for Immunotherapy, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  • Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Institute of Pathology, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.

ORCID-Profile: Tina M Schnöder, Federico Marini, Najla Abassi, Matthias M Gaida, Alina Henrich, Michaela N Höhne-Wiechmann, Tobias Bopp, Hansjörg Schild, Daniel Sasca, Florian H Heidel, Steffen Koschmieder, Hans Christian Probst, Markus P Radsak, Sabine Muth

Zitieren

APA

Lossa, J., Schnöder, T. M., Ronge, Z., Haasch, N., Hodapp, K., Marini, F., Abassi, N., Gaida, M. M., Lee, S. J., Henrich, A., Höhne-Wiechmann, M. N., Thull Mogollón, C., Schütze, K., Klein, M., Bopp, T., Schild, H., Sasca, D., Crodel, C., Heidel, F. H., …, & Muth, S. (2026). Type-I interferon–activated NK cells control polycythemia vera in vivo. Blood, 148(11), 1454-1465. https://doi.org/10.1182/blood.2026033951

Vancouver

Lossa J, Schnöder TM, Ronge Z, Haasch N, Hodapp K, Marini F, et al. Type-I interferon–activated NK cells control polycythemia vera in vivo. Blood. 2026;148(11):1454-1465. doi:10.1182/blood.2026033951

BibTeX
@article{Lossa2026,
  author = {Lossa, Johanna and Schnöder, Tina M and Ronge, Zora and Haasch, Nelly and Hodapp, Katrin and Marini, Federico and Abassi, Najla and Gaida, Matthias M and Lee, Shin-Jye and Henrich, Alina and Höhne-Wiechmann, Michaela N and Thull Mogollón, Carlos and Schütze, Kristian and Klein, Matthias and Bopp, Tobias and Schild, Hansjörg and Sasca, Daniel and Crodel, Carl and Heidel, Florian H and Koschmieder, Steffen and Probst, Hans Christian and Radsak, Markus P and Muth, Sabine},
  title = {Type-I interferon–activated NK cells control polycythemia vera in vivo},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {11},
  pages = {1454--1465},
  doi = {10.1182/blood.2026033951}
}
Kostenlos starten →